AU2017315357B2 - Combination therapies for the treatment of hepatocellular carcinoma - Google Patents

Combination therapies for the treatment of hepatocellular carcinoma Download PDF

Info

Publication number
AU2017315357B2
AU2017315357B2 AU2017315357A AU2017315357A AU2017315357B2 AU 2017315357 B2 AU2017315357 B2 AU 2017315357B2 AU 2017315357 A AU2017315357 A AU 2017315357A AU 2017315357 A AU2017315357 A AU 2017315357A AU 2017315357 B2 AU2017315357 B2 AU 2017315357B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
pyrimidin
amino
acceptable salt
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017315357A
Other languages
English (en)
Other versions
AU2017315357A1 (en
Inventor
Anand SELVARAJ
Peter Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2017315357A1 publication Critical patent/AU2017315357A1/en
Application granted granted Critical
Publication of AU2017315357B2 publication Critical patent/AU2017315357B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017315357A 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma Active AU2017315357B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378455P 2016-08-23 2016-08-23
US62/378,455 2016-08-23
PCT/US2017/048183 WO2018039324A1 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
AU2017315357A1 AU2017315357A1 (en) 2019-02-28
AU2017315357B2 true AU2017315357B2 (en) 2022-12-01

Family

ID=59772765

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017315357A Active AU2017315357B2 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Country Status (14)

Country Link
US (1) US20190175598A1 (enExample)
EP (1) EP3503923B1 (enExample)
JP (1) JP7190425B2 (enExample)
KR (1) KR102466192B1 (enExample)
CN (1) CN109803684B (enExample)
AU (1) AU2017315357B2 (enExample)
BR (1) BR112019003722A2 (enExample)
CA (1) CA3034875C (enExample)
ES (1) ES2966469T3 (enExample)
IL (1) IL264950B2 (enExample)
MX (1) MX2019002115A (enExample)
RU (1) RU2769251C2 (enExample)
SG (1) SG11201901472TA (enExample)
WO (1) WO2018039324A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
CA3100144C (en) 2018-05-14 2023-10-03 Pfizer Inc. Oral solution formulation of palbociclib in malic or lactic acid buffer
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
WO2021230886A1 (en) * 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
KR20250003965A (ko) 2022-05-30 2025-01-07 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 암 치료용 약학적 조합 및 약학적 조성물
CN120417928A (zh) * 2023-11-30 2025-08-01 石药集团中奇制药技术（石家庄）有限公司 联合治疗肿瘤的药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006368A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy
WO2015057938A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Pyrimidine fgfr4 inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
DK1252155T3 (da) 2000-01-18 2005-04-04 Aventis Pharma Inc Ethanolsolvat af (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-on
AU2001226346A1 (en) 2000-01-18 2001-07-31 Aventis Pharmaceuticals Inc. Pseudopolymorph of
US20050004007A1 (en) 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
JP4291696B2 (ja) 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
KR101345002B1 (ko) 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
KR101346886B1 (ko) 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
US20080161355A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
US20090263398A1 (en) 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
EP2046330A2 (en) 2006-07-14 2009-04-15 Astex Therapeutics Limited Pharmaceutical combinations
WO2008009954A1 (en) 2006-07-21 2008-01-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
ES2554513T3 (es) * 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
HRP20161092T1 (hr) 2010-10-25 2016-10-21 G1 Therapeutics, Inc. Cdk inhibitori
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
MX378263B (es) * 2013-08-14 2025-03-10 Novartis Ag Terapia de combinación para el tratamiento del cáncer.
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
US20160220569A1 (en) 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
CA2982562C (en) * 2015-04-14 2023-06-13 Eisai R&D Management Co., Ltd. Crystalline fgfr4 inhibitor compound and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006368A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy
WO2015057938A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Pyrimidine fgfr4 inhibitors

Also Published As

Publication number Publication date
EP3503923B1 (en) 2023-10-04
CA3034875C (en) 2024-05-28
CN109803684B (zh) 2022-08-23
CA3034875A1 (en) 2018-03-01
RU2019108259A3 (enExample) 2020-11-24
ES2966469T3 (es) 2024-04-22
IL264950B2 (en) 2024-01-01
RU2769251C2 (ru) 2022-03-29
JP7190425B2 (ja) 2022-12-15
IL264950B1 (en) 2023-09-01
RU2019108259A (ru) 2020-09-25
WO2018039324A1 (en) 2018-03-01
EP3503923A1 (en) 2019-07-03
CN109803684A (zh) 2019-05-24
BR112019003722A2 (pt) 2019-05-28
KR102466192B1 (ko) 2022-11-14
US20190175598A1 (en) 2019-06-13
SG11201901472TA (en) 2019-03-28
MX2019002115A (es) 2019-07-08
AU2017315357A1 (en) 2019-02-28
KR20190040996A (ko) 2019-04-19
JP2019528302A (ja) 2019-10-10
IL264950A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
AU2017315357B2 (en) Combination therapies for the treatment of hepatocellular carcinoma
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
AU2020300543A1 (en) System for enhancing therapeutic compliance of the anti-cancer compound E7766
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы
EP4667005A2 (en) Combination therapies for the treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)